Abstract
Background: Despite impressive efficacy in immunocompetent individuals, the immunogenicity of a single dose of COVID-19 vaccine in B-cell-deplete patients remains unknown.
Objectives: We aimed to quantify real-world vaccine immunogenicity in ocrelizumab recipients.
Methods: We measured post-vaccination SARS-COV-2 immunoglobulin G (IgG) in ocrelizumab recipients using a highly sensitive Luminex assay.
Results: 44.1% of patients had detectable SARS-COV-2-IgG 21+ days after one vaccine dose, regardless of vaccine type (AZD1222 vs BNT162b2, odds ratio (OR) = 0.62, 95% confidence interval (CI) = 0.157-2.32, p = 0.72). B-cell count strongly predicted seroconversion (β1 = 12.38, 95% CI = 4.59-20.16, p = 0.0029), but undetectable B-cells did not preclude it. The second vaccine seroconverted 53% of the patients who had not already responded to dose 1.
Conclusion: Humoral response after one COVID-19 vaccine dose is lower than expected in CD20-deplete patients.
Keywords: COVID-19; Ocrelizumab; SARS-COV-2; antibodies; vaccination.
【저자키워드】 COVID-19, antibodies, SARS-CoV-2, vaccination, Ocrelizumab, 【초록키워드】 IgG, Efficacy, Vaccine, COVID-19 vaccine, vaccination, immunogenicity, vaccine dose, BNT162b2, AZD1222, Immunoglobulin G, Seroconversion, Humoral response, Immunoglobulin, Patient, patients, single dose, Ocrelizumab, B-cell, CD20, dose, Odds ratio, B-cells, vaccine immunogenicity, 95% CI, 95% confidence interval, recipients, recipient, Luminex assay, predicted, the patient, detectable, seroconverted, individuals, expected, undetectable, 【제목키워드】 Vaccine, Patient, Relapsing-Remitting Multiple Sclerosis, diminished,